ArticleEuropean geriatric medicine2026
Assessing the risk of sarcopenia among community-dwelling older adults in Israel: a national cross-sectional survey.
Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWith aging population and the growing burden of sarcopenia on health systems, early risk assessment is essential. This study assessed the risk of sarcopenia and associated factors among community-dwelling older adults.
methodsThis cross-sectional study used data from the Israel National Elderly Falls Survey (2018-2019) among adults aged 65+ by the Israel Center for Disease Control. Data were collected via telephone interviews on demographic, health, and functional characteristics. Sarcopenia risk was assessed using the validated five-item Mini Sarcopenia Risk Assessment (MSRA-5) questionnaire, with a cutoff score of ≤ 45 indicating risk. Multivariable logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) for sarcopenia risk.
resultsA total of 2668 participants were included in the study, with a mean age of 73.2 ± 5.7 years, and 56.3% were female. Based on the MSRA-5 cutoff score (≤ 45), 65.1% (n = 1738) were classified as at risk for sarcopenia. Older age (OR = 1.21 per 5-year increase, 95% CI 1.10-1.33), Arab ethnicity (OR = 2.05, 95% CI 1.59-2.64), lower education level (OR = 1.57, 95% CI 1.29-1.92), and anxiety/depression (OR = 1.83, 95% CI 1.32-2.54) were associated with the prevalence of sarcopenia risk. Functional limitations, including difficulty performing household activities (OR = 1.96, 95% CI 1.42-2.69) and physical inactivity (OR = 1.72, 95% CI 1.40-2.11), were also associated with sarcopenia risk. A dose-response relationship was observed with medication use, with progressively higher odds of sarcopenia risk among those taking > 8 medications per day (OR = 2.75, 95% CI 1.52-4.98).
conclusionThese findings highlight the high prevalence of sarcopenia risk among older adults in Israel and emphasize the importance of early screening to identify at-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.